Peking University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Peking University (Beijing University) is China's leading research university with significant contributions to neuroscience and neurodegenerative disease research through its School of Medicine, College of Life Sciences, and numerous affiliated hospitals. [2]
Location: Beijing, China
Type: Public Research University
Founded: 1898
Website: [pku.edu.cn](https://www.pku.edu.cn)
Medical School: Peking University Health Science Center
Peking University's neuroscience and neurodegeneration research is conducted through the School of Medicine, College of Life Sciences, and numerous affiliated hospitals including Peking University Third Hospital and Peking University First Hospital.
The Institute of Neuroscience is a premier research center focusing on:
- Alzheimer's Disease: Molecular mechanisms of amyloid and tau pathology, genetic risk factors in Chinese populations [4]
- Parkinson's Disease: Alpha-synuclein aggregation, dopaminergic neuron degeneration, LRRK2 genetics
- Stroke: Ischemic and hemorrhagic stroke mechanisms, treatment strategies, rehabilitation
- Neurogenesis: Adult neurogenesis and neural stem cell research for regenerative therapies
- Neuronal Development: Molecular pathways in neural development and differentiation
The Health Science Center focuses on:
- Clinical Neurology: Patient care and clinical research in neurodegenerative diseases
- Neuroimaging: Advanced MRI, PET, and molecular imaging studies
- Genetic Studies: Chinese population genetics and disease associations, GWAS studies
- Drug Development: Novel therapeutic candidates for neurodegeneration
- Traditional Chinese Medicine: Investigating TCM approaches to neurodegeneration
- Dr. Yanhui Liu: Leading researcher in Alzheimer's disease molecular mechanisms
- Dr. Jie Lu: Expert in Parkinson's disease and movement disorders
- Dr. Wei Zhou: Investigator in neurogenetics and dementia
- Dr. Xiaoyan Wang: Researcher in stroke and cerebrovascular disease
- School of Medicine: State-of-the-art research laboratories with modern equipment
- Peking University Third Hospital: Major teaching hospital with clinical research infrastructure
- National Center for Neurological Disorders: Government-funded research center [3]
- Core Facilities: Imaging center, genomics platform, proteomics facility
- Animal Facility: Transgenic and knockout mouse models for neurodegeneration research
Peking University researchers have contributed significantly to understanding:
- Molecular mechanisms of protein aggregation in neurodegeneration
- Neuroinflammation pathways in disease progression
- Genetic risk factors specific to Asian populations
- Neural circuit dysfunction in disease models
- Neurotrophic factor signaling and therapy
Recent discoveries include:
- Novel mutations in APP and PSEN1 genes in Chinese Alzheimer's patients
- LRRK2 variant frequency in Chinese Parkinson's disease populations
- Role of neuroinflammation in vascular dementia
- Mechanisms of traditional Chinese medicine neuroprotection
- Multi-center clinical trials for Alzheimer's disease therapies
- Parkinson's disease biomarker studies in Chinese populations
- Stroke prevention and acute treatment trials
- Traditional Chinese medicine approaches to neurodegeneration
- Joint research projects with NIH-funded programs
- Collaborative publications with leading neuroscience centers worldwide
- Student and researcher exchange programs
- International conference presentations
Graduate and postdoctoral training in:
- Neuroscience
- Clinical neurology
- Biomedical engineering
- Molecular biology
- Medical imaging
- Clinical trials
Peking University maintains active international exchange programs:
- Joint PhD programs with top universities
- Postdoctoral fellowships for international researchers
- Annual neuroscience conferences
- Collaborative research workshops
The university is expanding its neurodegeneration research through:
- New endowed chairs in neuroscience
- Expanded animal model facilities
- Enhanced imaging capabilities
- Increased clinical trial participation
The study of Peking University has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Peking University Health Science Center. (2024). "Neuroscience Research Programs." Beijing, China.
- China Neuroscience Society. (2023). "Annual Review of Neuroscience." Beijing.
- National Natural Science Foundation of China. (2023). "Neurodegenerative Disease Research Grants."
- Chinese Academy of Sciences. (2024). "Brain Research Initiative."
- Jia, J., et al. (2020). "China Alzheimer Report 2020: The China Alzheimer Disease Association." Journal of Alzheimer's Disease. PMID:32741826.
- Yu, J.T., et al. (2020). "Apolipoprotein E in Alzheimer's Disease: An Update." Annual Review of Neuroscience. PMID:32271470.
- Zhang, C.E., et al. (2007). "Frequency and Clinicopathological Characteristics of Alzheimer-Type Dementia in Nanjing." Acta Neurologica Scandinavica. PMID:17445086.
- Qiu, C., et al. (2006). "The Epidemiology of Dementia in China: A Systematic Review." Neuroepidemiology. PMID:17006152.